Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program
| Autor: | Pamela Lenkov, Vasily Giannakeas, Kimberley A. Hill, Pavel Crystal, Petrina A. Causer, Steven A. Narod, Ping Sun, Martin J. Yaffe, Ellen Warner, Roberta A. Jong, Donald B. Plewes, Christine Elser, E. Ramsay, Jean M. Seely, Siqi Zhu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
medicine.medical_specialty BRCA2 gene medicine.medical_treatment Population lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Breast cancer breast neoplasms medicine magnetic resonance imaging Mammography 030212 general & internal medicine skin and connective tissue diseases education education.field_of_study medicine.diagnostic_test business.industry Obstetrics screening Cancer lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease mortality Annual Screening Cancer registry Standardized mortality ratio Oncology 030220 oncology & carcinogenesis BRCA1 gene business Mastectomy |
| Zdroj: | Cancers, Vol 12, Iss 3479, p 3479 (2020) Cancers Volume 12 Issue 11 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers12113479 |
| Popis: | Annual breast magnetic resonance imaging (MRI) plus mammography is the standard of care for screening women with inherited BRCA1/2 mutations. However, long-term breast cancer-related mortality with screening is unknown. Between 1997 and June 2011, 489 previously unaffected BRCA1/2 mutation carriers aged 25 to 65 years were screened with annual MRI plus mammography on our study. Thereafter, participants were eligible to continue MRI screening through the high-risk Ontario Breast Screening Program. In 2019, our data were linked to the Ontario Cancer Registry of Cancer Care Ontario to identify all incident cancers, vital status and causes of death. Observed breast cancer mortality was compared to expected mortality for age-matched women in the general population. There were 91 women diagnosed with breast cancer (72 invasive and 19 ductal carcinoma in situ (DCIS)) with median follow-up 7.4 (range: 0.1 to 19.2) years. Four deaths from breast cancer were observed, compared to 2.0 deaths expected (standardized mortality ratio (SMR) 2.0, p = 0.14). For the 489 women in the study, the probability of not dying of breast cancer at 20 years from the date of the first MRI was 98.2%. Annual screening with MRI plus mammography is a reasonable option for women who decline or defer risk-reducing mastectomy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|